GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Total Current Liabilities

Indaptus Therapeutics (Indaptus Therapeutics) Total Current Liabilities : $2.77 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Indaptus Therapeutics's total current liabilities for the quarter that ended in Dec. 2023 was $2.77

Indaptus Therapeutics Total Current Liabilities Historical Data

The historical data trend for Indaptus Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics Total Current Liabilities Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
2.02 4.60 3.43 2.77

Indaptus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 1.82 2.10 2.37 2.77

Indaptus Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Indaptus Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.459+0.102
+Other Current Liabilities+Current Deferred Liabilities
=1.213+0
=2.77

Indaptus Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.459+0.102
+Other Current Liabilities+Current Deferred Liabilities
=1.213+0
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Indaptus Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » Total Current Liabilities
Comparable Companies
FRES IGXT AURX CLCS ACER HARP AKTX SNSE BIXT PLUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Website
https://www.indaptusrx.com
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
Glen R. Anderson 10 percent owner 3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman officer: Chief Medical Officer C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell director 4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev officer: Chief Medical Officer 13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman director, 10 percent owner, officer: Chief Scientific Officer C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert director 13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee director, 10 percent owner C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397

Indaptus Therapeutics (Indaptus Therapeutics) Headlines

From GuruFocus

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

By Marketwired • 08-14-2023

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

By Stock market mentor Stock market mentor • 02-07-2023

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

By Marketwired • 08-10-2023

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews • 07-07-2022

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

By sperokesalga sperokesalga • 04-19-2023

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

By sperokesalga sperokesalga • 05-09-2023

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

By sperokesalga sperokesalga • 05-01-2023

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews • 07-03-2022

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

By sperokesalga sperokesalga • 04-19-2023

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

By GuruFocusNews GuruFocusNews • 06-28-2022